Humira (adalimumab) is a prescription drug that’s used to treat certain types of arthritis and other inflammation-related diseases. It comes as a liquid solution for injection under your skin ...

Humira has been the world’s best selling medicine since it arrived on the market in 2002. Now, it is finally getting competition with the release of Amgen’s biosimilar drug, Amjevita.

These first-person essays are part of a special series leading up to the 109th running of the Indianapolis 500 on May 25 on FOX in which INDYCAR drivers penned letters about what the historic race ...

Novartis' Sandoz division has filed its biosimilar of Humira in the US, aiming to take a share of its multi-billion dollar revenues once its patent expires. The generics and biosimilars arm of ...

With Skyrizi now capturing 1 in 3 in place UC patients, we highlight that the company’s I&I portfolio appears poised to continue growing through more significant Humira erosion,” analyst Evan ...

AbbVie has proved its resilience by becoming stronger after losing patent exclusivity for its blockbuster drug Humira. Johnson & Johnson is a seasoned dividend payer for all seasons. David ...

European regulators have backed a new Humira biosimilar for approval, setting up a four-way race for the blockbuster’s market share later this year between Amgen, Boehringer Ingelheim ...

A third of the way through the 2025 MLS season, CF Montreal are on the verge of history. Unfortunately for the club, it's not the side anyone wants to be on. Still in search of its first win ...

The pharmaceutical company, whose products include immunology treatments Skyrizi and Humira, as well as anti-wrinkle drug Botox, is the latest to outline plans to bolster its U.S. presence as the ...

(Ryan Remiorz/The Canadian Press) Elections Canada wants you to know your ballot will count whether you mark it with a pen or with a pencil. The independent agency says it's seeing posts on social ...

Sanofi’s development of an oral spin on Humira’s mechanism has hit a setback. The candidate fell short in a phase 2 psoriasis trial, prompting the French drugmaker to pull back from plans to ...

Medical device company Penumbra (NYSE:PEN) reported Q1 CY2025 results beating Wall Street’s revenue expectations , with sales up 16.3% year on year to $324.1 million. The company expects the ...